SCHEMBL12660596

SCHEMBL12660596

CCOC(=O)C(C)(CCCCOS(C)(=O)=O)C(=O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MMP9 P14780 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
CYP4F2 P78329 3/20 0.42
CYP4A11 Q02928 3/20 0.42
PKM P14618 3/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.38
MMP8 P22894 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
AMPD3 Q01432 1/20 0.34
CA1 P00915 5/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13359798 0.82 CYP4F2 (0.56) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL25249514 0.77 TSHR (0.44) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL6067652 0.77 MEN1 (0.54) ALDH1A1CYP4F2CYP4A11PKMTHRB
SCHEMBL14502372 0.75 MEN1 (0.57) CYP4F2CYP4A11PKMTHRBHTT
SCHEMBL10031336 0.75 CYP4F2 (0.70) KDM4EALDH1A1LMNAALOX15TSHR
SCHEMBL168851 0.75 CYP4F2 (0.46) KDM4EALDH1A1LMNAALOX15TSHR
SCHEMBL7510917 0.75 MEN1 (0.57) CYP4F2CYP4A11PKMTHRBHTT
SCHEMBL25189076 0.75 MEN1 (0.57) CYP4F2CYP4A11PKMTHRBHTT
SCHEMBL10631549 0.75 MEN1 (0.57) CYP4F2CYP4A11PKMTHRBHTT
SCHEMBL7508348 0.75 MEN1 (0.57) CYP4F2CYP4A11PKMTHRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947253-B2 compounds such as 2-methyl-2(3-fluoropropyl)-malonic Acid that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets APOSENSE LTD. (IL) 2011-05-24 US disclosed
US-7670590-B2 Perturbed membrane-binding compounds and methods of using the same APOSENSE LTD. (IL) 2010-03-02 US disclosed
US-20100035296-A1 COMPOUNDS AND METHODS FOR DETECTION OF CELLS APOSENSE LTD. (IL) 2010-02-11 US disclosed
US-20080279774-A1 Perturbed Membrane-Binding Compounds And Methods Of Using The Same NST NEUOROSURIVAL TECHNOLOGIES LTD. (IL) 2008-11-13 US disclosed
US-20080014148-A1 Perturbed membrane-binding compounds and methods of using the same APOSENSE LTD. (IL) 2008-01-17 US disclosed
US-7270799-B2 Perturbed membrane-binding compounds and methods of using the same NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) 2007-09-18 US disclosed
US-7270799-B2 Perturbed membrane-binding compounds and methods of using the same NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035296-A1 COMPOUNDS AND METHODS FOR DETECTION OF CELLS CASP3, BAX, BAD KDM4E 2361/4885USP2 1312/4885ALDH1A1 773/4885
US-20080014148-A1 Perturbed membrane-binding compounds and methods of using the same ANXA5, SELPLG, ANXA6 KDM4E 4400/4885USP2 4017/4885ALDH1A1 4144/4885
US-20080279774-A1 Perturbed Membrane-Binding Compounds And Methods Of Using The Same ANXA5, SELPLG, ANXA6 KDM4E 4400/4885USP2 4017/4885ALDH1A1 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.